Pariceract

Pariceract (INNTooltip International Nonproprietary Name; developmental code name BIA 28-6156 or LTI-291) is a β-glucocerebrosidase (GCase) activator or positive allosteric modulator which is under development for the treatment of Parkinson's disease.^{[1][2][3][4][5]} It is taken orally.^[1] GCase is a lysosomal enzyme encoded by the gene GBA1.^[4][5] Loss-of-function mutations in this gene are thought to promote α-synuclein accumulation and are among the leading genetic risk factors for Parkinson's disease.^[4][5][6] As such, activation of GCase might provide a disease-modifying therapy for treatment of Parkinson's disease.^[4][5] Pariceract was first described in the scientific literature by 2017.^[6] It was originated by Lysosomal Therapeutics and is under development by Lysosomal Therapeutics and Bial.^[1][2][3] As of October 2025, it is in phase 2 clinical trials.^[1][2][3]

Other namesBIA 28-6156; LTI-291; LIT291; LTI-00291

Routes of
administrationOral^[1]

Drug classβ-Glucocerebrosidase (GCase) activator or positive allosteric modulator

CAS Number

• 1919820-28-2

Quick facts Clinical data, Other names ...

Pariceract

Clinical data
Other names	BIA 28-6156; LTI-291; LIT291; LTI-00291
Routes of administration	Oral[1]
Drug class	β-Glucocerebrosidase (GCase) activator or positive allosteric modulator
Identifiers
IUPAC name 5,7-dimethyl-N-(4-pentoxycyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
CAS Number	1919820-28-2
PubChem CID	121327414
ChemSpider	68028144
UNII	V9WUN9UUU8
Chemical and physical data
Formula	C20H30N4O2
Molar mass	358.486 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCOC1CCC(CC1)NC(=O)C2=C3N=C(C=C(N3N=C2)C)C
InChI InChI=1S/C20H30N4O2/c1-4-5-6-11-26-17-9-7-16(8-10-17)23-20(25)18-13-21-24-15(3)12-14(2)22-19(18)24/h12-13,16-17H,4-11H2,1-3H3,(H,23,25) Key:HZILSILAELSWKN-UHFFFAOYSA-N

Close